Clinical Trial

The Dragon PLC Trial (DRAGON-PLC)

Recruiting
View on ClinicalTrials.gov →
Summary
The goal of the DRAGON PLC clinical trial is to determine whether portal vein embolization (PVE) combined with hepatic vein embolization (HVE) improves resectability and overall survival in patients with initially unresectable primary liver cancer compared to standard PVE alone. This trial specifically focuses on patients with hepatocellular carcinoma and cholangiocarcinoma. The main questions this trial aims to answer are whether combined PVE and HVE increases the proportion of patients who become resectable within 3 weeks and improves 5-year overall survival compared to PVE alone by enhancing liver hypertrophy. Participants will: * Undergo either standard PVE or combined PVE and HVE. * Have regular imaging to assess liver resectability. * Be monitored for survival outcomes up to 5 years after intervention.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-31.
Status change: Not Yet Recruiting → Recruiting 2025-05-12
Trial Details
NCT Number NCT06914648
Lead Sponsor Maastricht University
Conditions Primary Liver Cancer, Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
Enrollment 358 participants
Start Date 2025-04-01
Primary Completion 2032-11-15 (estimated)
Study Completion 2032-11-15 (estimated)
Updated on ClinicalTrials.gov 2025-05-15